Datapoint: AbbVie Scores Ulcerative Colitis Nod for Rinvoq

The FDA last week approved AbbVie’s Rinvoq for the treatment of ulcerative colitis, the JAK inhibitor’s third label expansion in the past four months. Rinvoq was first approved in rheumatoid arthritis in 2019. For the treatment of the disease, the JAK inhibitor holds covered or better status for 96% of all insured lives. 36% of all covered lives have preferred access to Rinvoq, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 3/23/22

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 11

Datapoint: Amylyx Pulls ALS Drug Off the Market

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 10

Datapoint: FDA Grants J&J’s Carvykti Earlier, Expanded Use in Multiple Myeloma

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
April 9

Datapoint: GA Medicaid Expansion Could Bring Coverage to 300,000 People

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today